Amgen Funds UK Patient Groups Over £200,000
Biotechnology company Amgen has provided over £200,000 in funding to various UK patient advocacy groups for 2025. The grants support initiatives for conditions including blood cancers, thyroid disorders, and inflammatory bowel disease.
Biotechnology firm Amgen has allocated more than £200,000 to support several patient advocacy groups in the United Kingdom throughout 2025. The funding targets a range of health conditions, from blood cancers and thyroid disorders to inflammatory bowel diseases and rare genetic conditions.
The largest single grant, exceeding £839,000, was awarded to World Child Cancer UK to support a project focused on improving early detection and access to treatment for childhood cancer. Leukaemia Care received £13,000 for the production of patient support videos, and the ITP Support Association received £25,000 to support its patients' convention.
Other recipients include Blood Cancer UK, which received £10,500 for research and support activities, and the British Thyroid Foundation, granted £30,400 for a patient information day on thyroid eye disease. Amgen also provided £2,000 to Crohn's & Colitis UK to assist staff attendance at a conference.
The funding supports various initiatives such as educational programmes, information days, and research. Amgen representatives also participated in internal meetings and advisory panels for some organisations, with separate honoraria and expenses paid.
Amgen's US division provided $5,000 to the Global Porphyria Advocacy Coalition for website development. The company also supported HEART UK with multiple grants totalling over £69,900 for initiatives related to familial hypercholesterolaemia (FH) cascade testing and a conference sponsorship.